De Bortoli A, Nordøy I, Connelly JP, Viermyr HK, Bjerkreim RH, Broch K, Olsen PAS, Gude E, Fevang B, Jørgensen SF, Trøseid M, Steen T, Aukrust P, Andreassen AK, Skarpengland T(2024) Diagnostics, treatment and outcomes of cardiac sarcoidosis in a Norwegian cohort Int J Cardiol, 400, 131809 DOI 10.1016/j.ijcard.2024.131809, PubMed 38272129
Hites M, Lapique EL, Massonnaud CR, Belhadi D, Jamard S, Goehringer F, Danion F, Reignier J, de Castro N, Garot D, Lacombe K, Tolsma V, Faure E, Malvy D, Staub T, Courjon J, Cazenave-Roblot F, Dyrhol Riise AM, Leturnier P, Martin-Blondel G, Roger C, Akinosoglou K, Moing VL, Piroth L, Sellier Pet al.(2024) Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial J Infect, 88(3), 106120 DOI 10.1016/j.jinf.2024.106120, PubMed 38367705
Jørgensen SF, Macpherson ME, Bjørnetrø T, Holm K, Kummen M, Rashidi A, Michelsen AE, Lekva T, Halvorsen B, Trøseid M, Mollnes TE, Berge RK, Yndestad A, Ueland T, Karlsen TH, Aukrust P, Hov JR, Fevang B(2024) Retraction Note: Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency Sci Rep, 14(1), 3704 DOI 10.1038/s41598-024-54117-6, PubMed 38355714